Praxis Precision price target lowered to $85 from $150 at Needham
Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing Ulixa sales from its model after the company disclosed ...
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide
Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating on PRAX stock remains as a "Hold".
Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01
LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced ...
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...